Roche’s MS drug fenebrutinib delivers striking Phase III results by cutting relapse rates by 58%
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
The Eurasian Patent Organization (EAPO) has granted Patent, protecting the company’s sublingual delivery technology for anticancer drugs used to treat autoimmune and neurodegenerative diseases
Subscribe To Our Newsletter & Stay Updated